Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 23638367)

1.

Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells.

Small GW, McLeod HL, Richards KL.

PeerJ. 2013 Feb 12;1:e31. doi: 10.7717/peerj.31. Print 2013.

2.

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS.

Br J Haematol. 2012 Feb;156(4):490-8. doi: 10.1111/j.1365-2141.2011.08966.x. Epub 2011 Dec 9.

PMID:
22150234
3.

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.

Clin Cancer Res. 2008 Mar 1;14(5):1561-70. doi: 10.1158/1078-0432.CCR-07-1254.

4.
5.

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.

Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.

Leuk Res. 2006 May;30(5):625-31. Epub 2005 Nov 11.

PMID:
16289746
6.

New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.

Robak T, Robak E.

BioDrugs. 2011 Feb 1;25(1):13-25. doi: 10.2165/11539590-000000000-00000. Review.

PMID:
21090841
8.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
9.
10.

Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.

Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B.

Int J Oncol. 2009 Dec;35(6):1289-96.

PMID:
19885551
11.

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.

J Immunother. 2001 May-Jun;24(3):263-71.

PMID:
11394505
12.

Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).

Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.

Int J Oncol. 2007 Jul;31(1):29-40.

PMID:
17549402
13.

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M.

Blood. 2000 Jun 15;95(12):3900-8.

14.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

15.
16.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253
17.

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.

Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y.

Leukemia. 2010 Oct;24(10):1760-8. doi: 10.1038/leu.2010.157. Epub 2010 Aug 5.

PMID:
20686505
18.

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Braza MS, Klein B, Fiol G, Rossi JF.

Haematologica. 2011 Mar;96(3):400-7. doi: 10.3324/haematol.2010.029520. Epub 2010 Nov 25.

19.

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Cheson BD.

J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10. Review.

PMID:
20458041
20.

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.

Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R.

Cancer Sci. 2009 Dec;100(12):2411-8. doi: 10.1111/j.1349-7006.2009.01327.x. Epub 2009 Aug 25.

PMID:
19758394
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk